Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 41, 2011 - Issue 9
Submit an article Journal homepage
408
Views
5
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs

J.A. Clarkson-JonesAstraZeneca, Alderley Park, Macclesfield, UKCorrespondence[email protected]
,
A.S.J. KenyonAstraZeneca, Alderley Park, Macclesfield, UK
&
H.K. TomkinsonAstraZeneca, Alderley Park, Macclesfield, UK
Pages 784-796 | Received 26 Nov 2010, Accepted 09 Feb 2011, Published online: 10 Jun 2011

References

  • Bagnato A, Natali PG. (2004). Endothelin receptors as novel targets in tumor therapy. J Transl Med 2:16.
  • Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD. (2002). Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838–844.
  • Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484.
  • Curtis N, Howard Z, Brooks N, Curwen J. (2004). ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects. Eur J Cancer Suppl 2:27.
  • Fujita Y, Yamada Y, Kusama M, Yamauchi T, Kamon J, Kadowaki T, Iga T. (2003). Sex differences in the pharmacokinetics of pioglitazone in rats. Comp Biochem Physiol C Toxicol Pharmacol 136:85–94.
  • Growcott JW. (2009). Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 20:83–88.
  • James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D, Dawson NA. (2010). Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106:966–973.
  • Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60:277–300.
  • Kasper S, Cookson MS. (2006). Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 33:201–210.
  • Kopetz ES, Nelson JB, Carducci MA. (2002). Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 20:173–182.
  • Lenz EM, Kenyon A, Martin S, Temesi D, Clarkson-Jones J, Tomkinson H. (2011). The metabolism of [14C]-zibotentan in rat, dog and human, the loss of the radiolabel and the identification of a mysterious peak derived from the animal feed. J Pharm Biomed Anal 55:500–517.
  • Liu XD, Xie L, Zhong Y, Li CX. (2000). Gender difference in letrozole pharmacokinetics in rats. Acta Pharmacol Sin 21:680–684.
  • McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD. (2004). Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119:174–186.
  • Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. (2005). Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 92:2148–2152.
  • Mugford CA, Kedderis GL. (1998). Sex-dependent metabolism of xenobiotics. Drug Metab Rev 30:441–498.
  • Nelson J, Bagnato A, Battistini B, Nisen P. (2003). The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110–116.
  • Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. (1998). Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 273:12584–12592.
  • Petrylak D. (2005). Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 96 Suppl 2:41–46.
  • Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520.
  • Sapirstein LA, Vidt DG, Mandel MJ, Hanusek G. (1955). Volumes of distribution and clearances of intravenously injected creatinine in the dog. Am J Physiol 181:330–336.
  • Tomkinson HK, Weil A, Engelhardt E, Schmid K, Oliver S. (2009). An open-label study of the pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in subjects with mild, moderate, or severe renal impairment, or normal renal function. Eur J Cancer Suppl 7:132.
  • Waxman DJ, O’Connor C. (2006). Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 20:2613–2629.
  • Yang SH, Yang KH, Lee MG. (2008). Gender differences in ondansetron pharmacokinetics in rats. Biopharm Drug Dispos 29:406–413.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.